Variant · Amplification
ALK Amplification
CI-VAR-00000247Explore in graph →CIViC 4301
Curated evidence
Evidence by cancer (6 items)
Grouped by cancer context first, then therapy. The same variant can be sensitizing in one cancer and irrelevant in another — contexts are never merged. 50 items per page; a cancer group may continue on the next page.
- Source
- CIViC — Clinical Interpretation of Variants in Cancer
- Dataset
- CIViC evidence items
- Version
- civic-2026-09-08
- Retrieved
- Sep 8, 2026
- Layer
- normalized (units and labels harmonized; values unchanged)
- Evidence
- expert curation
- License
- CC0 1.0
- PMID
- 26791794
- Run
- ING-CIVIC-20260908-000001
| Molecular profile | Therapy | Type | Level | Direction · significance | Rating (1–5) | Status | Evidence | Source |
|---|---|---|---|---|---|---|---|---|
| Lung Adenocarcinoma1 | ||||||||
| MET Amplification OR ALK Amplification OR ROS1 Amplification | Crizotinib | Predictive | D | Supports Sensitivity Response | 3 | submitted | EID11386Lung adenocarcinoma cell lines (H3122: EML4-ALK E13:A20, HCC78: SLC34A2-ROS1, H1993: MET amplification, and H596: MET exon 14 skipping) with putative crizotinib-sensitive genotypes were analyzed with … (full text at CIViC) PMID 26791794 · Jorge et al., 2015 · Open in CIViC | civic |
| Lung Non-Small Cell Carcinoma4 | ||||||||
| ALK G1269A AND EML4::ALK e6::e19 AND ALK Amplification | Crizotinib | Predictive | C | Supports Resistance | 3 | submitted | EID8887This study analyzed patients with non small cell lung cancer (NSCLC) who were positive for EML4-ALK fusions (ALK+) and progressed on crizotinib monotherapy. One ALK+ patient had a novel fusion between… | |
ClinVar
Clinical significance (0)
ClinVar interpretations are shown as structured records — significance, review status, star rating, conditions — never flattened into one word.
Data not yet available